An early study of first generation asthma diagnostic apps identified many were unvalidated, contained errors and offered therapeutic interventions that were not evidence based.
Since those early days clinicians, policy groups and regulators have actively discussed the quality and safety aspects of app development and there is now, supposedly, a greater understanding of the potential risks. To support this, more resources have been targeted at medical app developers, aiming to improve the quality and safety of medical apps.
However, a recent study appears to suggest nothing much has changed. While choice has increased, newer apps for asthma were no more likely than the first generation to satisfy evidence-based recommendations for information content or the design of self-management tools. And issues of quality and safety identified in first-generation apps were still apparent.